Interferon α-1b Combined with Lamivudine in the Sequential Treatment of Children with Chronic Hepatitis B

Li Bo; Zheng Huanwei

doi:10.13407/j.cnki.jpp.1672-108X.2020.05.004

您当前的位置：

首页 >

文章列表页 >

Interferon α-1b Combined with Lamivudine in the Sequential Treatment of Children with Chronic Hepatitis B

更新时间：2022-11-03

- Interferon α-1b Combined with Lamivudine in the Sequential Treatment of Children with Chronic Hepatitis B
- Vol. 26, Issue 5, Pages: 12-16(2020)
- 作者机构：
  
  石家庄市第五医院,河北,石家庄,050024
- 作者简介：
- 基金信息：
- DOI：10.13407/j.cnki.jpp.1672-108X.2020.05.004
  CLC：
- Published：2020，
  
  Published Online：10 May 2020，
扫描看全文
Li Bo, Zheng Huanwei. Interferon α-1b Combined with Lamivudine in the Sequential Treatment of Children with Chronic Hepatitis B. [J]. 26(5):12-16(2020)
DOI：

Li Bo, Zheng Huanwei. Interferon α-1b Combined with Lamivudine in the Sequential Treatment of Children with Chronic Hepatitis B. [J]. 26(5):12-16(2020) DOI： 10.13407/j.cnki.jpp.1672-108X.2020.05.004.

摘要

目的：探讨干扰素α-1b序贯拉米夫定联合治疗小儿慢性乙型肝炎的疗效及其对肝功能、病毒学的影响。方法：选取2015年11月至2017年5月我院收治的慢性乙型肝炎患儿136例，根据随机数表分为研究组和对照组各68例。对照组仅给予干扰素α-1b，肌肉注射，隔日1次，每次30 μg/m2，连续治疗1个月后，改为每次60 μg/m2，隔日肌肉注射1次，连续治疗6个月。研究组采用干扰素α-1b与拉米夫定序贯治疗，首先口服拉米夫定，每日按3 mg/kg顿服，连续治疗1个月，后肌肉注射干扰素α-1b。观察两组患儿治疗前及治疗后1、3、6个月肝功能、病毒学水平，并进行疗效评价。结果：两组治疗后1、3、6个月丙氨酸氨基转移酶（ALT）、天门冬氨酸氨基转移酶（AST）和总胆红素（TBIL）水平均低于治疗前，且呈降低趋势，差异均有统计学意义（P<0.05）；研究组治疗后1、3、6个月ALT、AST和TBIL水平均低于对照组，差异有统计学意义（P<0.05）。两组治疗后1、3、6个月乙型肝炎病毒e抗原（HBeAg）水平均低于治疗前（P<0.05）；对照组治疗后6个月HBV-DNA水平低于治疗前及治疗后1个月，差异有统计学意义（P<0.05）；研究组治疗后1、3、6个月HBV-DNA水平均低于治疗前，且治疗后3、6个月低于治疗后1个月，差异均有统计学意义（P<0.05）；研究组治疗后3、6个月HBeAg、HBV-DNA水平均低于对照组，差异有统计学意义（P<0.05）；研究组治疗后6个月HBeAg转阴率高于对照组（P<0.05）；对照组治疗后6个月HBeAg转阴率高于治疗后1、3个月，治疗后3、6个月HBeAg转换率高于治疗后1个月，差异均有统计学意义（P<0.05）；研究组治疗后3、6个月HBV-DNA应答率高于治疗后1个月（P<0.05），治疗后6个月HBeAg转阴率高于治疗后1、3个月，治疗后3、6个月HBeAg转换率高于治疗后1个月，差异均有统计学意义（P<0.05）。结论：干扰素α-1b与拉米夫定序贯治疗小儿慢性乙型肝炎可显著改善患儿肝功能，抑制乙肝病毒活性，提高HBeAg转阴率，临床效果优于单用干扰素α-1b。

Abstract

Objective: To probe into the efficacy of interferon α-1b combined with lamivudine in the sequential treatment of children with chronic hepatitis B and its effects on liver function and virology. Methods: A total of 136 children with chronic hepatitis B admitted into our hospital from Nov. 2015 to May 2017 were extracted to be divided into the study group and the control group via the random number table

with 68 cases in each group. The control group was treated with interferon α-1b in intramuscular injection

once every other day

30 μg/m2 each time

after 1 month of continuous treatment

the patients were given 60 μg/m2 each time in intramuscular injection

once every other day

for 6 months. The study group was given interferon α-1b combined with lamivudine

lamivudine was taken orally

3 mg/kg daily for 1 month

followed by intramuscular injection of interferon α-1b with the same dose of the control group. Liver function and virology of two groups were observed before treatment and after treatment of 1

3 and 6 months. Efficacy was evaluated after treatment. Results: The levels of alanine aminotransferase (ALT)

aspartate aminotransferase (AST) and total bilirubin (TBIL) of two groups were lower than those before treatment and after treatment of 1

3 and 6 months

with a decreasing trend

and the differences were statistically significant (P<0.05). The levels of ALT

AST and TBIL in the study group were lower than those in the control group after treatment of 1

and 6 months

and the difference was statistically significant (P<0.05). After treatment of 1

3 and 6 months

the levels of hepatitis B E antigen (HBeAg) in both groups were lower than those before treatment (P<0.05); the levels of HBV-DNA in the control group after treatment of 6 months was lower than those before treatment and after treatment of 1 month

the difference was statistically significant (P<0.05). The levels of HBV-DNA in the study group after treatment of 1

3 and 6 months were lower than those before treatment

and the data after treatment of 3 and 6 months were lower than those after treatment of 1 month

with statistically significant difference (P<0.05). The levels of HBeAg and HBV-DNA in the study group were lower than those in the control group after treatment of 3 and 6 months

the difference was statistically significant (P<0.05). The negative conversion rate of HBeAg in the study group was higher than that in the control group after treatment of 6 months (P<0.05). The negative conversion rate of HBeAg in the control group after treatment of 6 months was higher than that after treatment of 1 and 3 months

the negative conversion rate of HBeAg after treatment of 3 and 6 months was higher than that after treatment of 1 month

the difference was statistically significant (P<0.05). The response rate of HBV-DNA in the study group after treatment of 3 and 6 months was higher than that after treatment of 1 month

the negative conversion rate of HBeAg after treatment of 3 and 6 months was higher than that after treatment of 1 month

the difference was statistically significant (P<0.05). Conclusion: Interferon α-1b combined with lamivudine in the sequential treatment of children with chronic hepatitis B can significantly improve the liver function of children

inhibit hepatitis B virology

and increase the negative conversion rate of HBeAg. The clinical efficacy of interferon α-1b combined with lamivudine in the sequential treatment is better than interferon α-1b alone.

关键词

乙型肝炎儿童干扰素拉米夫定

Keywords

hepatitis Bhepatitischildrennterferonlamivudine

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy of of Interferon Combined with Yanhuning on Hand, Foot and Mouth Disease in Children and Its Effects on Nuclear Factor-κB and Related Factors

Analysis of 36 Cases of Drug Poisoning in Children in a Grade III, Level A General Hospital andConsideration on Pharmaceutical Care

Application of Dexmedetomidine Combined with Hydromorphone Nasal Drip in Sedation of Mother-InfantSeparation before Adenoidectomy

Sirolimus in the Treatment of 5 Cases of Blue Rubber Bleb Nevus Syndrome in Children and Literature Review

Systematic Review on Efficacy and Safety of Zoledronic Acid in the Treatment of Bone Metabolic Disordersin Children

Related Author

Li Xueguang

Su Zhiheng

Liang Qiyue

Gao Chengsi

Wang Peng

Xu Ying

Zhang Xiaoming

Zhang Shaonan

Related Institution

The Third People’s Hospital of Haikou

Pharmaceutical College, Guangxi Medical University

The Second People’ s Hospital of Anhui Wuhu, Anhui Wuhu

Jiangsu Taizhou People’s Hospital, Jiangsu Taizhou

Children’s Hospital Affiliated to Zhengzhou University,Henan Children’s Hospital, Zhengzhou Children’s Hospital, Zhengzhou Key Laboratory of Children’s Digestive Diseases

⁰